Profile data is unavailable for this security.
About the company
Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The Company is focused on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), in its Phase II ALTITUDE-AD clinical trial following Phase I results in early AD patients (patients with mild cognitive impairment or mild dementia due to AD). Sabirnetug is a recombinant humanized immunoglobulin gamma 2 (IgG2), monoclonal antibody (mAb) that selectively targets the anti-amyloid-beta oligomer, has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic mouse models for AD. The Company is developing sabirnetug for IV administration once every four weeks (Q4W) for the treatment of early AD, and it has developing sabirnetug for subcutaneous administration.
- Revenue in USD (TTM)0.00
- Net income in USD-133.35m
- Incorporated1996
- Employees61.00
- LocationAcumen Pharmaceuticals Inc1210-1220 Washington Street, Suite 210NEWTON 02465United StatesUSA
- Phone+1 (617) 344-4190
- Fax+1 (302) 636-5454
- Websitehttps://acumenpharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | 10.50m | -111.77m | 173.51m | 131.00 | -- | 2.67 | -- | 16.52 | -1.47 | -1.47 | 0.1382 | 1.03 | 0.0719 | -- | -- | 80,152.67 | -76.56 | -47.36 | -88.86 | -51.44 | -- | -- | -1,064.50 | -7,615.23 | -- | -- | 0.00 | -- | -- | -- | -4.38 | -- | -0.4137 | -- |
| Caribou Biosciences Inc | 9.30m | -157.13m | 177.59m | 147.00 | -- | 1.25 | -- | 19.11 | -1.70 | -1.70 | 0.1004 | 1.52 | 0.0345 | -- | 6.57 | 63,231.29 | -58.27 | -30.69 | -65.59 | -33.30 | -- | -- | -1,690.45 | -562.81 | -- | -- | 0.00 | -- | -71.01 | 11.54 | -46.08 | -- | 40.73 | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -12.84m | 182.54m | 8.00 | -- | 18.73 | -- | -- | -0.1136 | -0.1136 | 0.00 | 0.0774 | 0.00 | -- | -- | 0.00 | -93.18 | -57.21 | -231.54 | -73.22 | -- | -- | -- | -- | -- | -- | 0.0115 | -- | -- | -- | 32.94 | -- | 37.77 | -- |
| Sagimet Biosciences Inc | 0.00 | -57.67m | 185.70m | 14.00 | -- | 1.56 | -- | -- | -1.79 | -1.79 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -38.04 | -40.69 | -39.78 | -43.01 | -- | -- | -- | -6,987.70 | -- | -- | 0.00 | -- | -100.00 | -- | -63.46 | -- | -- | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -133.35m | 190.20m | 61.00 | -- | 2.04 | -- | -- | -2.21 | -2.21 | 0.00 | 1.54 | 0.00 | -- | -- | 0.00 | -65.18 | -33.77 | -72.61 | -35.61 | -- | -- | -- | -21,273.47 | -- | -- | 0.2475 | -- | -- | -- | -95.39 | -- | -- | -- |
| Vaxart Inc | 148.20m | -50.70m | 190.86m | 105.00 | -- | 6.80 | -- | 1.29 | -0.2222 | -0.2222 | 0.6495 | 0.1169 | 0.789 | -- | 3.31 | 1,411,467.00 | -26.99 | -49.90 | -80.48 | -58.33 | -- | -- | -34.21 | -875.06 | -- | -31.43 | 0.1161 | -- | 288.94 | 23.82 | 18.82 | -- | -8.21 | -- |
| Canton Strategic Holdings Inc | 0.00 | -10.32m | 191.29m | 2.00 | -- | 5.94 | -- | -- | -4.11 | -4.11 | 0.00 | 0.854 | 0.00 | -- | -- | 0.00 | -159.36 | -169.40 | -225.01 | -410.04 | -- | -- | -- | -- | -- | -- | 0.0255 | -- | -- | -- | -30.89 | -- | -- | -- |
| Nkarta Inc | 0.00 | -102.61m | 191.78m | 105.00 | -- | 0.5675 | -- | -- | -1.39 | -1.39 | 0.00 | 4.76 | 0.00 | -- | -- | 0.00 | -21.39 | -29.78 | -22.36 | -31.23 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.41 | -- | 17.99 | -- |
| Galectin Therapeutics Inc | 0.00 | -37.44m | 192.13m | 15.00 | -- | -- | -- | -- | -0.5913 | -0.5913 | 0.00 | -1.92 | 0.00 | -- | -- | 0.00 | -178.33 | -117.54 | -- | -197.34 | -- | -- | -- | -- | -- | -3.57 | -- | -- | -- | -- | -5.35 | -- | -- | -- |
| SAB Biotherapeutics Inc | 114.70k | -21.37m | 195.19m | 63.00 | -- | 1.18 | 8.88 | 1,701.73 | -2.81 | -2.81 | 0.0043 | 3.48 | 0.001 | -- | 0.3492 | 1,820.64 | 15.80 | -- | 17.22 | -- | -- | -- | 16,338.04 | -- | -- | -- | 0.0197 | -- | -40.94 | -- | 19.17 | -- | -- | -- |
| Kalaris Therapeutics Inc | 0.00 | -51.71m | 195.63m | 6.00 | -- | 4.67 | -- | -- | -87.38 | -87.38 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -50.77 | -52.59 | -52.70 | -57.65 | -- | -- | -- | -- | -- | -- | 0.4338 | -- | -- | -- | 69.14 | -- | -- | -- |
| Cartesian Therapeutics Inc | 1.93m | -50.61m | 197.37m | 66.00 | -- | -- | -- | 102.42 | -1.97 | -1.97 | 0.0743 | -1.38 | 0.0047 | -- | 0.6943 | 29,196.97 | -11.59 | -33.50 | -12.10 | -45.25 | -- | -- | -2,489.83 | -128.46 | -- | -- | -- | -- | 49.64 | 42.27 | 69.90 | -- | 186.63 | -- |
| Insight Molecular Diagnostics Inc | 4.40m | -60.78m | 199.24m | 46.00 | -- | -- | -- | 45.26 | -2.83 | -2.83 | 0.1643 | -0.3213 | 0.0771 | 5.67 | 18.85 | 95,695.65 | -106.49 | -41.57 | -124.80 | -46.86 | 54.73 | 24.70 | -1,380.69 | -2,290.77 | 2.73 | -171.82 | -- | -- | 25.15 | -- | -136.17 | -- | -10.88 | -- |
| Quantum-Si Inc | 3.18m | -116.85m | 206.09m | 143.00 | -- | 0.8763 | -- | 64.87 | -0.6589 | -0.6589 | 0.0176 | 1.09 | 0.0128 | 0.404 | 3.58 | 22,216.78 | -47.06 | -- | -50.90 | -- | 51.65 | -- | -3,677.97 | -11,135.53 | 10.59 | -- | 0.00 | -- | 182.62 | -- | -5.26 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -26.44m | 206.73m | 12.00 | -- | 2.83 | -- | -- | -0.2835 | -0.2835 | 0.00 | 0.7964 | 0.00 | -- | -- | 0.00 | -31.94 | -44.73 | -33.64 | -57.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.52 | -- | -- | -- |
Data as of Feb 27 2026. Currency figures normalised to Acumen Pharmaceuticals Inc's reporting currency: US Dollar USD
42.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2025 | 14.93m | 24.65% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 2.31m | 3.81% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2025 | 2.03m | 3.35% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.47m | 2.43% |
| Alyeska Investment Group LPas of 31 Dec 2025 | 939.60k | 1.55% |
| Adar1 Capital Management LLCas of 31 Dec 2025 | 891.18k | 1.47% |
| Laurion Capital Management LPas of 31 Dec 2025 | 867.05k | 1.43% |
| Pathstone Family Office LLCas of 31 Dec 2025 | 859.11k | 1.42% |
| Hudson Bay Capital Management LPas of 31 Dec 2025 | 725.00k | 1.20% |
| Millennium Management LLCas of 31 Dec 2025 | 584.14k | 0.96% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
